Aptose Biosciences Reports Q1 2026 Results and Acquisition Update
Aptose Biosciences Inc. announced its financial results for the first quarter ended March 31, 2026, alongside significant corporate updates regarding its acquisition by Hanmi Pharmaceutical and clinical trial progress. The closing of the acquisition arrangement has been delayed due to pending Korean regulatory approvals, though both parties aim to complete the transaction in May 2026. Under the agreement, Aptose shareholders will receive C$2.41 per share, representing a 28% premium. Clinically, Aptose highlighted robust data from its TUSCANY Phase 1/2 trial, which evaluates tuspetinib in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML). Updated findings from this trial, including new data on higher dose levels and safety profiles, have been selected for an oral presentation at the upcoming European Hematology Association (EHA) Congress in June 2026. The company continues to position its triple-drug therapy as a well-tolerated, mutation-agnostic frontline treatment option for AML patients ineligible for induction chemotherapy, particularly those with adverse mutation profiles such as TP53.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection